India's eye-care sector is drawing investor attention as Maxivision Super Specialty Eye Hospitals, a chain backed by private equity firm Quadria Capital, has taken the first steps toward a public listing. The company has hired ICICI Securities and IIFL Capital to advise on an initial public offering (IPO) targeted for 2027, according to people familiar with the matter.
The planned share sale is expected to include both fresh shares to raise capital for expansion and an offer for sale (OFS) allowing existing investors, including Quadria, to partially exit their holdings. This dual structure is common in Indian IPOs, where companies use new funds for growth while giving early backers a chance to cash out.
What is Maxivision?
Maxivision operates a network of super specialty eye hospitals across India, offering services such as cataract surgery, LASIK, and treatment for retinal disorders. The chain focuses on tier-2 and tier-3 cities, where demand for affordable, high-quality eye care is rising as incomes grow and awareness of preventive health increases.
Quadria Capital, a healthcare-focused private equity firm, invested in Maxivision to help scale its operations. The firm typically backs companies in Asia's healthcare sector, including hospitals, diagnostics, and pharmaceutical services.
Why 2027?
The three-year timeline suggests Maxivision and its bankers plan to use the period to strengthen financials, expand the hospital network, and build a track record that appeals to public market investors. Many Indian healthcare companies have successfully listed after similar preparation phases, benefiting from the country's growing medical tourism and domestic demand for specialized care.
India's IPO market has been active, with several healthcare and hospital chains going public in recent years. For example, the National Stock Exchange (NSE) itself is preparing for a listing, as India's NSE Takes IPO Roadshow Global Ahead of October Listing. The broader market has also seen strong performances from companies like Tata Consultancy Services (TCS), whose revenue beats have lifted Indian stocks, as noted in TCS Revenue Beat Lifts Indian Stocks as Oil Prices Hold Steady.
What it means for investors
For everyday investors, the Maxivision IPO represents an opportunity to gain exposure to India's healthcare sector, which is expected to grow as the population ages and medical spending rises. Eye care, in particular, is a recurring need—many patients require multiple visits over a lifetime—which can provide stable revenue for hospitals.
However, investors should note that IPOs carry risks. The company's valuation will depend on its financial performance over the next few years, and the success of the offering hinges on market conditions in 2027. Additionally, the inclusion of an OFS means some existing investors may sell shares, which could dilute the impact of new capital raised.
Quadria's involvement adds a layer of credibility, as private equity backing often signals rigorous due diligence. But investors should watch for details on the company's debt levels, profitability, and expansion plans when the draft red herring prospectus (DRHP) is filed with regulators closer to the listing date.
Broader context
India's healthcare IPO pipeline remains robust, with several hospital chains and diagnostic firms eyeing public markets. The country's favorable demographics—a large, young population with increasing health awareness—support long-term demand. Meanwhile, the rupee has been relatively stable, helped by lower oil prices, as seen in Rupee Steadies as Brent Crude Drops 2%, Offering Relief to India's Oil-Dependent Economy. This stability can attract foreign investment into Indian equities, including IPOs.
Maxivision's focus on super specialty eye care differentiates it from general hospitals, potentially allowing it to command higher margins. However, competition from established players like Dr. Agarwal's Eye Hospital and Aravind Eye Care means the company must demonstrate a clear growth strategy.
For now, the appointment of ICICI Securities and IIFL Capital—two well-known investment banks in India—signals that Maxivision is serious about its listing plans. Investors should keep an eye on the company's progress over the next few years, as the IPO could become a notable event in India's healthcare equity story.
